Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
Biological E Limited, a Hyderabad-based vaccine manufacturer, today launched 'Jeev' - a vaccine to fight against Japanese Encephalitis (JE) for the domestic market. Addressing the media here, Mahima Datla, senior vice president, Biological E, said, "The vaccine has been launched for the private markets targeting children and adults. Later, it …
The Supreme Court on Tuesday came down heavily on the Central government for delay in finalising a new drug-pricing policy which will determine prices at which pharma companies can sell essential medicines in the retail market. The apex court, while observing that the government might not find it appropriate if …
The government has allowed 100 per cent FDI in brownfield pharmaceutical projects. To encourage the needed foreign investment in the sector, the finance ministry has cleared eight projects worth over Rs 1,800 crore putting in only conditions like minimum investment in R&D; for investors to comply with. The approval puts …
The Indian Medical Association has morphed into a body representing the trade and commerce of medicine rather than the practice of medicine as a whole. Given the increasingly commercial and corporatised nature of healthcare, organisations like the IMA should provide leadership and a sense of direction to the individual medical …
New Delhi: Over-the-counter sale of around 92 antibiotic and anti-tuberculosis drugs in India will be restricted soon. Drug Controller General of India G N Singh has written to the Union health minister to notify a new schedule, H1, in the Drugs and Cosmetics Rules. Once notified, following clearance from the …
Cos which have taken corrective action after being penalised for violating FDA norms have been allowed to resume sales Most Indian drug companies that were penalised for violating US drug manufacturing norms in the last few years but have subsequently taken corrective actions are being allowed to resume sales by …
Mumbai: In yet another instance of India Inc occupying a larger seat in the global league tables, three out of the top 10 fastest-growing generic companies globally are now from India. Besides being an indication of the acceptance of domestic pharmaceutical companies and their growing clout, this is also a …
14 New Drug Molecules Approved Between Jan & July 2012, Only 9 Tested: Azad New Delhi: Drugs continue to be approved in India without having undergone proper clinical trials on the local population. Just months after the parliamentary standing committee on health exposed how the country’s highest office on drugs— …
Lack of compensation norms for clinical trials results in exploitation of poor patients Drug companies paid as little as . 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing …
Novartis patent case up for hearing this week; judgment to have far-reaching impact Mumbai/London: The Supreme Court will hear final arguments starting this week in a landmark case over drug patents that could change the rules for the country's healthcare sector and potentially curb its global role as a supplier …
New Delhi: As many as 211 people died between January and June 2012 due to serious adverse events (SAE) during clinical trials. Investigations are now on to ascertain how many of the deaths were caused by drugs administered to the trial subjects. Union health minister Ghulam Nabi Azad said on …
Nodal body for FDI policy DIPP to issue clarifications, paving the way for FIPB to take up pending proposals of Pfizer, B Braun & Sutures India The government is likely to clear next week foreign direct investment proposals worth over . 3,000 crore, by companies including Pfizer, B Braun and …
Health activists have strongly opposed the draft guidelines brought out by the Central Drugs Standard Control Organisation (CDSCO) on the quantum of financial compensation to be paid in case of clinical trial-related injury or death, saying age and income could not be the lone criteria for calculating the amount. The …
A recent ruling by Germany's Supreme Court has caused a public storm over the ethical conduct of doctors and drug companies in the country. Rob Hyde reports from Hamburg.
Aaron Kesselheim and colleagues investigate conflict of interest disclosures in articles authored by physicians and scientists identified in whistleblower complaints alleging illegal off-label marketing by pharmaceutical companies. Original Source
Mandatory ethics panel oversight, explanation within 30 days of a death & compensation rules coming The Union health ministry and the drug regulator’s office are preparing to introduce norms and notifications to monitor clinical trials in a better way. In the wake of criticism of the existing guidelines, the ministry …
The young, the healthy and those earning more stand to get greater compensation if they suffer any untoward incident during a clinical trial. The Drug Controller General of India on Friday came out with new guidelines for determing the quantum of financial compensation to be paid in case of a …
Companies say they follow global standards in India as well Drug majors such as Novartis, Pfizer, Bayer Healthcare, Bristol Mayer Squibb, Sun Pharmaceutical and Dr Reddy’s Laboratories were allegedly involved in clinical trials in which 438 persons died in 2011, according to confidential government data reviewed by Business Standard. While …
New Delhi A suo motu study on drug pricing by the Ministry of Corporate Affairs has revealed exorbitant profit margins on 21 common drugs manufactured by Indian companies. Though pricing regulations of the National Pharmaceutical Pricing Authority (NPPA) say that companies can keep a profit margin of maximum 100 per …
